tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Imugene Limited Announces Quotation of New Securities on ASX

Story Highlights
Imugene Limited Announces Quotation of New Securities on ASX

Elevate Your Investing Strategy:

The latest announcement is out from Imugene ( (AU:IMU) ).

Imugene Limited has announced the application for quotation of 92,495 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategic efforts to strengthen its financial position and support its ongoing development projects in cancer immunotherapy, potentially impacting its market positioning and offering new opportunities for stakeholders.

The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited operates in the biotechnology industry, focusing on the development of innovative immunotherapies for cancer treatment. The company is committed to enhancing the immune system’s ability to fight cancer, with a market focus on advancing its pipeline of oncology products.

Average Trading Volume: 560,858

Technical Sentiment Signal: Sell

Current Market Cap: A$93.35M

For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1